Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib
T D Kim(Charité - Universitätsmedizin Berlin), Phillipp D. Le Coutre(Charité - Universitätsmedizin Berlin), Gianantonio Rosti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Luciano Levato(Azienda Ospedaliera Pugliese Ciaccio), Ivo Buschmann(Charité - Universitätsmedizin Berlin), Delphine Réa(Institut Bergonié), Francis J. Giles(National University of Ireland), Peggy Grille(Charité - Universitätsmedizin Berlin), Ruhdja Lindhorst(Charité - Universitätsmedizin Berlin), Wilhelm Haverkamp(Charité - Universitätsmedizin Berlin), Bernd Dörken(Charité - Universitätsmedizin Berlin), Michaela Schwarz(Charité - Universitätsmedizin Berlin), Franck E. Nicolini(Hôpital Edouard Herriot), Hervé Dombret(University of London Institute in Paris), Hélène Labussière(Hôpital Lyon Sud), Tristan Mirault
Cited by 233
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Genotype-Phenotype Correlation in the Long-QT Syndrome
|Circulation|2001|1.8k